Hypoxic-Ischemic Encephalopathy (HIE) in Neonates
Definition
HIE in the term neonate is a neonatal encephalopathy (NE) with a constellation of clinical features and characteristic topography of brain lesions on MRI, resulting from reduced blood flow and oxygen delivery to the brain and excessive accumulation of metabolites — most often mediated by impaired perinatal placental gas exchange.
It applies to neonates ≥ 35 weeks' gestational age.
Pathophysiology
When oxygenated blood supply is limited:
- The fetus initially adapts: increased O₂–hemoglobin binding, preferential shunting to high-risk tissues
- Regions with highest metabolic demand are most vulnerable: Rolandic cortex, thalamus, and basal ganglia
- After the initial insult and reperfusion → transient recovery → then secondary energy failure due to:
- Excitotoxicity
- Apoptosis
- Reactive oxygen species
- Inflammation
This biphasic injury (primary phase → latent phase → secondary phase) is the mechanistic basis for the therapeutic window for cooling.
Etiology / Risk Factors
During pregnancy:
- Gestational diabetes, IUGR, preeclampsia, pregnancy-induced hypertension
During labor & delivery:
- Non-reassuring fetal heart rate tracing
- Placental abruption
- Cord accident (prolapse, nuchal cord)
- Low cord pH / low Apgar scores
- Need for neonatal resuscitation
Diagnosis
ACOG/AAP diagnostic criteria (2014, reaffirmed 2020) require:
- Clinical features of NE (altered consciousness, seizures, abnormal tone/reflexes, respiratory depression) in neonate ≥ 35 weeks
- Neonatal signs consistent with acute peripartum event — at least one of:
- Apgar score < 5 at 5 and 10 minutes
- Umbilical artery pH < 7.0 or base deficit ≥ 12 mmol/L
- Acute brain injury on MRI/MRS consistent with hypoxia-ischemia
- Multisystem organ failure consistent with HIE
- Sentinel hypoxic/ischemic event during labor/delivery (e.g., uterine rupture, abruption, maternal cardiac arrest)
- Developmental outcome: spastic quadriplegia or dyskinetic cerebral palsy
Staging — Sarnat Classification
| Category | Mild (Stage 1) | Moderate (Stage 2) | Severe (Stage 3) |
|---|
| Consciousness | Hyperalert / ↑ | Lethargic / ↓ | Stupor or coma / ↓↓ |
| Spontaneous activity | Normal | ↓ | ↓↓ |
| Tone | Mild distal flexion | ↓ | ↓↓ (flaccid) |
| Muscle stretch reflexes | ↑ | ↓ | ↓↓ |
| Suck reflex | ↓ | ↓ | ↓↓ |
| Moro reflex | ↑ | ↓ | ↓↓ |
| Autonomic system | Sympathetic | Parasympathetic | ↓↓ |
| Clinical seizures | None | ++ (common) | + (uncommon) |
| EEG background | Normal | ↓ | ↓↓ |
| Poor outcome | ~0% | 20–40% | ~100% |
| Duration | < 24 hr | > 24 hr (variable) | > 5 days |
Neuroimaging
MRI is the modality of choice — two predominant injury patterns:
(A) Basal ganglia-thalamus pattern — involves ventrolateral thalami, posterior putamina, perirolandic cortex; typically follows acute sentinel event (e.g., cord prolapse)
(B) Watershed-predominant pattern — anterior-middle and posterior-middle cerebral artery watershed zones; typically follows prolonged partial asphyxia without a clear sentinel event
DWI timing: Restriction peaks within a few days, "pseudonormalizes" by ~1 week. T1/T2 changes begin day 3–4. Optimal MRI timing: day 3–4 (after hypothermia ends).
MR spectroscopy: elevated lactate:N-acetyl aspartate ratio carries prognostic value.
Management
1. Supportive Care
- Resuscitation, airway management
- Correction of metabolic derangements (glucose, electrolytes, acid-base)
- Continuous EEG monitoring + aggressive seizure management
2. Therapeutic Hypothermia (Cooling) ★
The only proven neuroprotective intervention.
Indications (≥ 36 weeks' gestation, within 6 hours of delivery):
- Umbilical cord pH < 7.0 or base excess > 16 mmol/L within 1 hour of delivery, OR
- Moderate to severe encephalopathy on clinical exam
Protocol:
- Target temperature: 33–33.5°C for 72 hours
- Administered as total body cooling or head cooling
- Must be at an experienced comprehensive neonatal center
Efficacy: Meta-analysis of 11 RCTs showed statistically significant reduction in combined mortality or major neurodevelopmental disability at 18 months. NNT = 7.
3. Adjunct / Investigational
- Erythropoietin — under study; may reduce injury
- Melatonin, xenon — investigational neuroprotectants
Prognosis
Despite therapeutic hypothermia, mortality + neurodevelopmental morbidity in moderate-severe HIE remains ~50%.
| Severity | Outcome |
|---|
| Mild | Usually no significant neurodevelopmental sequelae |
| Moderate | Unpredictable; resolution by day 5 is a favorable sign |
| Severe | Death or severe impairment: spastic quadriparesis, intellectual disability, cortical visual impairment, epilepsy |
Almost half of neonates with HIE who survive have some neurodevelopmental sequelae.
Sources: Bradley and Daroff's Neurology in Clinical Practice; Creasy & Resnik's Maternal-Fetal Medicine; The Harriet Lane Handbook 23e; Rosen's Emergency Medicine